Tag - CERE

Cerevel Therapeutics (NASDAQ:CERE) dosed the first patients in each of its three Phase 3 trials evaluating tavapadon for the treatment of Parkinson’s disease (PD).  Tavapadon is an oral, once-daily partial agonist...